Watchlist Price Alert

Heron Therapeutics Inc. (HRTX)

NASDAQ: HRTX · Real-Time Price · USD

2.13

-0.03 (-1.39%)

At close: Jun 27, 2025, 3:59 PM

2.11

-1.17%

After-hours: Jun 27, 2025, 05:43 PM EDT

-1.39% (1D)

Bid	2.11
Market Cap	325.72M
Revenue (ttm)	157.98M
Net Income (ttm)	-7.79M
EPS (ttm)	-0.05
PE Ratio (ttm)	-42.7
Forward PE	30.86
Analyst	Buy

Ask	2.14
Volume	889,208
Avg. Volume (20D)	1,481,848
Open	2.16
Previous Close	2.16
Day's Range	2.10 - 2.19
52-Week Range	1.04 - 3.73
Beta	1.17

About HRTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol HRTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for HRTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Heron Therapeutics Inc. is scheduled to release its earnings on Aug 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+13.62%

Heron Therapeutics shares are trading higher after... Unlock content with Pro Subscription

4 months ago

+20.49%

Heron Therapeutics shares are trading higher following better-than-expected Q4 financial results.

News

1 month ago · seekingalpha.com

Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025

HRTX's Q1'25 earnings highlight Cinvanti as the top earner, but Zynrelef shows strong growth potential, with 60% growth in net sales vs Q1'24. HRTX reported net income of $2.6M and raised its full-yea...

1 month ago · seekingalpha.com

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer I...

1 month ago · zacks.com

Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metric...

1 month ago · zacks.com

Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates

Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago.

1 month ago · zacks.com

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.